What groups of drugs are used for itching? The conclusion first
To state the conclusion first, professional sources describe the drugs used for itching and allergy not as one drug but as several groups. In its treatment section, the canine atopic dermatitis entry of the Merck Veterinary Manual covers, in turn, glucocorticoids (steroids), the JAK inhibitors oclacitinib and ilunocitinib, the monoclonal antibody lokivetmab, cyclosporine, antihistamines, essential fatty acids, allergen-specific immunotherapy, external parasite control, treatment of secondary infections, and topical care such as medicated baths. Each group works differently and takes a different amount of time to show an effect, so it is hard to say in one sentence that one group is better than another.
This article arranges that classification in a way that is easy for pet owners to follow. What causes itching and when to see a veterinarian are covered in another article (health-itchy-skin-causes), so they are not explained again here; the focus is on which kinds of drugs a veterinarian chooses from once the cause has been determined.
A few things should be stated up front. This article does not tell you how to choose or give a drug. Drug names are written mainly as the generic names that appear in the sources, and doses and dosing intervals are not given. Even for the same drug, approval and evidence differ between dogs and cats, and the right choice changes with age, existing illnesses and other medicines in use. The side effects of steroids are touched on here only at the level of classification and are not covered in detail.
The content below is also an editorial draft, and no veterinary or pharmacy review has taken place. If you are thinking of substituting a human medicine at home or a drug made for another animal, consult an animal hospital first, before looking for the drug.
What should be checked before choosing a drug?
The Merck Veterinary Manual explains that when a dog with atopic dermatitis has an acute flare, the current flea control approach should be checked and, if needed, flea control should be started. On the feline side, the same manual's entry on feline atopic skin syndrome introduces flea allergy dermatitis as the most common allergic skin disease in cats and explains that for a cat with itchy dermatitis, checking or starting flea control is essential. The Cornell University Feline Health Center also advises that when there is a flea allergy, the animal and its surroundings must be managed together. In other words, the first step in any discussion of itch drugs is external parasite control, not a drug.
The second thing to check is secondary infection. The Merck Veterinary Manual explains that Staphylococcus and Malassezia infections are common in dogs with atopic dermatitis and often worsen the signs. For cats, it explains that when infection is confirmed by cytology, antimicrobials can help reduce the severity of lesions, and that topical treatment is preferred over systemic administration where possible. This should not be read as meaning that antibiotics or antifungals are used in advance on itchy skin; it means that a test to confirm whether an infection is actually present comes first.
The reason for looking at external parasites and infection like this is that, for the same itching, other itch drugs may not settle the signs well if these two are not resolved. Put the other way, itching that quiets down for a while on a drug does not necessarily mean the cause has gone away. This is also why knowing the groups of drugs helps: if you know at which stage a drug is used, it is easier to understand why the hospital recommends tests or management first.
In summary, drugs for itching are tools that each play a role within a broad flow of external parasite control, infection checks and allergy management. What to do in what order is decided by the veterinarian according to the examination findings.
What do the sources explain for each group?
Glucocorticoids (steroids) are a group that the Merck Veterinary Manual handles in two forms, oral and topical. It explains that oral prednisone and prednisolone produce a broad, nonspecific anti-inflammatory response, and advises that long-term use carries a high risk of side effects. Topical steroids are used for acute flares and localized lesions; the manual explains that prolonged use can cause problems such as changes in adrenal function or skin atrophy, and that they are suited to short periods. Detailed side effects are outside the scope of this article, so only the classification is introduced here.
The JAK inhibitors oclacitinib and ilunocitinib appear in the Merck Veterinary Manual. The manual describes oclacitinib as a fast-acting itch suppressant with mild anti-inflammatory activity and states that it is approved for dogs older than 12 months. It advises that the drug is contraindicated in dogs with serious infections or tumors, that it may increase susceptibility to infections, demodicosis and neoplastic conditions, and that blood changes such as decreased white blood cell and lymphocyte counts and increased liver enzymes have been reported as side effects. The US approved label (the oclacitinib label published on DailyMed) likewise states that it is not for use in dogs younger than 12 months or in dogs with serious infections, and that dogs should be watched for infections and tumors.
The monoclonal antibody lokivetmab is described by the Merck Veterinary Manual as a canine-specific monoclonal antibody that targets IL-31, an itch-inducing cytokine. The same source states that no age restriction or known drug interactions have been reported, and that the common adverse events are lethargy and digestive signs. However, the cat entry does not cover lokivetmab and says only that the role of IL-31 in feline allergic disease has not been established.
Cyclosporine is described as a slow-acting drug, taking up to 4–6 weeks to take effect. In dogs, digestive upset is common, and secondary infections, excessive hair growth and gum overgrowth are reported rarely. In the cat entry, vomiting, diarrhea and loss of appetite are described as common, and fatal toxoplasmosis has been reported in cats that had not been infected before.
The Merck Veterinary Manual describes antihistamines as working best when given before a flare occurs, while advising that they have very little effect in acute flares. Essential fatty acids can take up to 2 months and are of no use for controlling acute flares, and the manual explains that there is no evidence that any particular combination is better. Allergen immunotherapy is a method that aims to raise tolerance to allergens; the manual states that adverse events are rare, that the most common is increased itching, and that anaphylaxis is reported very rarely.
| Group | Mode of action (as the sources describe it) | Cautions the sources list |
|---|---|---|
| Glucocorticoids (steroids) | Broad, nonspecific anti-inflammatory response | Merck: oral drugs carry a high risk of side effects with long-term use, and topical drugs may cause changes in adrenal function and skin atrophy with prolonged use |
| JAK inhibitors (oclacitinib, ilunocitinib) | Quickly reduce itching, with mild anti-inflammatory activity | Not for use under 12 months, not for use with serious infections, watch for infections, demodicosis and tumors, blood and liver enzyme changes reported |
| Monoclonal antibody (lokivetmab) | Targets IL-31 (an itch-inducing cytokine) | Merck: no age restriction, common adverse events are lethargy and digestive signs, not covered in the cat entry |
| Cyclosporine | Modulates the immune response (the source does not explain the action separately) | 4–6 weeks to effect, digestive upset, rarely secondary infections and others, toxoplasmosis reported in cats |
| Antihistamines | Block the action of histamine | Very little effect in acute flares, small and limited benefit in cats, sedation reported |
| Essential fatty acids | The source does not explain the action separately | Of no use for controlling acute flares, up to 2 months to effect, no evidence that a particular combination is better |
| Allergen immunotherapy | A method that aims to reduce allergic reactions by raising tolerance | Adverse events are rare (increased itching is the most common), anaphylaxis reported rarely, in cats judged after 1 year |
| External parasite control | Removes triggers such as fleas | Merck and Cornell: check first in itchy animals |
| Antimicrobials and antifungals | Treat secondary bacterial and yeast infections | Merck (cats): may help when infection is confirmed by cytology, and topical treatment is preferred where possible |
How are cats described differently from dogs?
The Merck Veterinary Manual's entry on feline atopic skin syndrome covers the same groups of drugs as for dogs, but makes clear that approval and evidence differ from those for dogs. The biggest difference is oclacitinib. The manual states that this drug has US FDA approval for canine atopic dermatitis but is not approved for feline atopic skin syndrome. While noting that there are studies showing an effect in cats, it explains that using it is extra-label use, that there are no long-term safety data, and that close monitoring is needed. This article does not mean that dog drugs should be used in cats. It conveys that extra-label use is an area where a veterinarian weighs risk and benefit.
For glucocorticoids, the manual explains that systemic administration is effective and fast in most cats, and advises checking blood, serum biochemistry and urine tests at regular intervals because of the long-term risks. Topical steroids can also be absorbed and cause side effects, so it says they need to be watched when used for a long time. For cyclosporine, it introduces several studies showing an effect on atopic reactions in cats, while also listing the digestive upset and toxoplasmosis risk seen above.
For antihistamines, it introduces a 2021 analysis in which some cats had a small, limited benefit, and says the most common adverse event is sedation. For essential fatty acids, it explains that limited data support a moderate effect but that no general recommendation can be made. Allergen immunotherapy is used in a similar way as in dogs, but the manual advises that skin test results are harder to read in cats, and introduces the point that owners need to be prepared to continue for 1 year before judging the effect.
The problem of human medicines for cats is covered in a separate article (health-human-medicine-for-pets). Cats process drugs differently from dogs, so transferring drugs used in dogs, or human medicines, can be dangerous. That is why the explanation for cats must always be checked separately, even for an ingredient with the same name.
How are these drugs classified and sold in Korea?
In Korea, drugs used for animals are managed under rules separate from human drugs. The current Regulation on the Designation of Prescription Veterinary Drugs (처방대상 동물용의약품 지정에 관한 규정), as opened on the National Law Information Center (Ministry of Agriculture, Food and Rural Affairs Public Notice No. 2020-90, partially amended on November 12, 2020, in force from November 13, 2021), states in its purpose clause that, under Article 85, paragraphs 6 and 7 of the Pharmaceutical Affairs Act (약사법), it sets the scope of veterinary drugs that a person licensed as a veterinary drug wholesaler or a veterinary pharmacy (동물약국) opener must not sell without a prescription from a veterinarian or an aquatic animal disease control specialist.
Article 2 lists, as drugs that a person licensed as a veterinary drug wholesaler must not sell without a prescription, anesthetics, hormones, antibiotics and antibacterials, biological products specified in Annex 4, and drugs whose active ingredient is a substance specified in Annex 5 (drugs that require a veterinarian's expertise). Article 3 lists, as drugs that a veterinary pharmacy opener must not sell without a prescription, injectable antibiotic preparations and injectable biological products. In the current version that was opened, Annexes 1 to 3 are marked as deleted. The 2017 version of the same regulation (No. 2017-43) carries a notice that it is not the current version, so this article is based on the current version.
The list of active ingredients in Annex 5 (active ingredients of veterinary drugs that require expertise), as opened, includes several ingredients from the groups mentioned in this article. For glucocorticoids it shows Prednisolone, Dexamethasone, Hydrocortisone (oral and injectable forms only) and Triamcinolone (oral and injectable forms only); for JAK inhibitors, Oclacitinib maleate; and for immunosuppressants, Cyclosporine (oral and injectable forms only). Veterinary drugs with these ingredients as active ingredients fall under the drugs that a wholesaler must not sell without a prescription. By contrast, what the regulation lists for veterinary pharmacy openers is only the two categories in Article 3, so this article does not state how these ingredients can be bought at a veterinary pharmacy. The list contains an entry called Monoclonal antibody, but the name lokivetmab was not seen, and antihistamine ingredients were not found on the list screen as opened. However, because the list was read as a screen image, it cannot be said that the entire list was checked line by line.
Also, what the regulation sets is only a sales restriction based on active ingredient; it does not say whether products with those ingredients are approved and sold in Korea, or for which animal species they are approved. So whether a specific product is a prescription item should be confirmed at the animal hospital or veterinary pharmacy you use, and the regulation itself is best checked directly on the National Law Information Center.
One more point to stress is that the foreign approval information in this article does not stand in for Korean approval. The age restrictions and warnings in the US approved label for oclacitinib (published on DailyMed) are US approval matters, and this article does not say that they are the same as the approval details of products sold in Korea. Drugs used in Korea must follow the veterinarian's prescription and the product's package insert.
What should be read differently from overseas sources?
First, approval and sales structures differ from country to country. The JAK inhibitor information in this article comes from the US approved label and the Merck Veterinary Manual, and the label's wording to use only on the order of a veterinarian is also phrasing from US federal law. In Korea, as seen in the previous section, there is a separate prescription-designation regulation, so the way the same ingredient is sold may differ.
Second, the dates of the sources differ. For ilunocitinib, the Merck Veterinary Manual cites a 2025 safety study and explains that the drug is used in dogs 12 months and older, is contraindicated when there is a serious infection, and requires a drug-free period before and after vaccination. For newer drugs, the approval wording and warnings may change, so it cannot be assumed that what is written in this article is the same as the current label. This article could not open and check the US approved label for ilunocitinib directly and conveys only the explanation in the Merck Veterinary Manual.
Third, this article could not confirm the approving authority and status of lokivetmab. The Merck Veterinary Manual explains the nature of the drug and its adverse events, but which authority in which country approved it could not be confirmed in the sources that were opened, so it is not stated.
Fourth, the level of evidence for immunotherapy. The Merck Veterinary Manual says the reported effect differs from study to study, and explains that the transdermal route comes from a study of 6 animals and that larger studies are needed. So ranking any group on the grounds that it is “newer” or “has been used longer” does not match the sources.
What can owners check?
If an itch drug has been prescribed, the items an owner can check are arranged in the table below. The table turns the cautions listed in the sources into questions; judgment is left to the veterinarian, and owners can use it to ask questions and take notes during the visit.
- Ask the veterinarian which group the drug belongs to, and whether it is a drug that reduces itching or one that reduces inflammation.
- Check whether the animal's age and species fit the drug's approved use, and if the use is extra-label, what the reason is.
- Tell the veterinarian in advance if there is a history of infection, tumors or demodex mites. The JAK inhibitor label says to weigh risk and benefit in dogs with such a history.
- Tell the veterinarian about all other medicines and supplements already being given. The label states that use of oclacitinib together with other immunosuppressants, such as glucocorticoids or cyclosporine, has not been evaluated.
- Ask how long the drug takes to take effect. The sources explain that cyclosporine and essential fatty acids are not drugs that quickly bring an acute flare under control.
- Ask which warning signs should prompt a call, and whether there are items to be checked by blood test.
- If the dog is being bred, or is pregnant or nursing, be sure to say so. The US approved label for oclacitinib (published on DailyMed) states that it is not for use in breeding dogs or in pregnant or nursing dogs.
This list is not a standard for evaluating a prescription. Judging whether a prescription is right is not the owner's job, and for questions it is most accurate to ask the prescribing veterinarian directly.
| Question | Related basis in the sources | What to note down |
|---|---|---|
| What group is this drug in, and what is its role? | Merck: the mode of action and the time to effect differ by group | Drug generic name, group |
| Is it a drug approved for my pet's age and species? | Oclacitinib is approved for dogs 12 months and older and not approved for cats (Merck) | Whether it is extra-label use |
| Did I tell the veterinarian about any infection or tumor history? | Infection- and tumor-related warnings on the JAK inhibitor label | List of past medical history |
| Did I tell the veterinarian about all the medicines given together? | Label: use with other immunosuppressants has not been evaluated | List of drugs and supplements |
| When will the effect be judged? | Cyclosporine 4–6 weeks, essential fatty acids up to 2 months (Merck) | Start date, progress |
| What signs should prompt a call? | Merck: adverse events differ by drug | Warning signs and contact number |
What are some common misunderstandings?
The first misunderstanding is the idea that “all itch drugs are the same kind of drug.” As seen above, steroids, JAK inhibitors, monoclonal antibodies and cyclosporine differ in mode of action and cautions. Even if the names sound similar, they are not drugs that can be swapped for one another.
The second is the idea that “antihistamines are safe, so just try them first.” The Merck Veterinary Manual explains that antihistamines have very little effect in acute flares but can be used together with other treatments to manage chronic disease, and says that a small, limited benefit has also been found in cats. The risk of giving human allergy medicine on one's own is covered in a separate article (health-human-medicine-for-pets). This article does not recommend antihistamines; it only conveys the sources' explanation that the effect is weak.
The third is the idea that “an injected antibody is not really a drug, so there is no burden.” The Merck Veterinary Manual lists lethargy and digestive signs as common adverse events of lokivetmab. Whatever form a drug takes, it cannot be assumed to have no adverse events, so it is advisable to watch the animal's condition after the injection and tell the veterinarian.
The fourth is the idea that “when the itching stops, the cause is also solved.” As seen above, itching can return if external parasites and secondary infection remain. The Merck Veterinary Manual also treats atopic dermatitis as a disease that needs long-term management, and explains that with immunotherapy too, time is needed before the effect can be judged.
The fifth is the idea that “it is a veterinary drug, so it can be used the same way in dogs and cats.” The Merck Veterinary Manual explains that oclacitinib is approved for canine atopic dermatitis but not approved for cats. Remember that approval and evidence differ by species.
When should you contact a veterinarian?
If you are using an itch drug or about to, it is advisable to contact an animal hospital in the following cases: when the itching does not settle even with the drug or keeps getting worse, when the skin bleeds or oozes or has a strong smell, when the areas where hair falls out at once are widening, and when vomiting or diarrhea continues or the animal is more subdued than usual and not eating. Whatever the type of drug, a veterinarian needs to check these changes.
The Merck Veterinary Manual explains that JAK inhibitors may increase susceptibility to infections and tumors, and the label says to watch for the development of infections and tumors. So while a pet is on this drug, if you see a new lump, repeated skin infections or scratches that were not there before, tell the veterinarian without waiting for the next appointment date. After immunotherapy, there is the possibility of anaphylaxis, for which the Merck Veterinary Manual advises observation for at least 30 minutes after administration, so if the face swells, breathing looks difficult or the animal collapses, go to an animal hospital or emergency care right away.
If digestive signs or lethargy appear after a drug is given, contact the veterinarian with the drug name, the time it was given and the number of remaining tablets. Do not stop a prescribed drug or change its dose on your own; whether a change is needed should be discussed with the veterinarian who prescribed it. It is worth stressing again that another animal's or a person's drug should not be given instead.
Frequently asked questions
Q What kinds of drugs are used for itching?
The Merck Veterinary Manual divides drugs for canine atopic dermatitis into glucocorticoids, JAK inhibitors (oclacitinib, ilunocitinib), a monoclonal antibody (lokivetmab), cyclosporine, antihistamines, essential fatty acids and allergen immunotherapy, and also covers external parasite control and treatment of secondary infections. Which drug to use is decided by the veterinarian.
Q What cautions apply to oclacitinib?
The Merck Veterinary Manual explains that it is approved for dogs older than 12 months and is contraindicated in dogs with serious infections or tumors. The US approved label (published on DailyMed) also states that it is not for use in dogs younger than 12 months or in dogs with serious infections, and that dogs should be watched for infections and tumors. It also states that it is not for use in breeding dogs or in pregnant or nursing dogs.
Q Will giving an antihistamine settle the itching?
The Merck Veterinary Manual explains that antihistamines have very little effect in acute flares, and the cat entry introduces a small, limited benefit in some cats. Do not give human allergy medicine on your own; talk to a veterinarian first.
Q Can a dog's itch drug be used for a cat?
It should not be used on your own. The Merck Veterinary Manual explains that oclacitinib is approved for dogs and not approved for feline atopic skin syndrome, that using it in cats is extra-label use, and that there are no long-term safety data. Extra-label use is a decision for the veterinarian.
Q Should antibiotics or antifungals be used first on itchy skin?
No source was found that explains it that way. The Merck Veterinary Manual says Staphylococcus and Malassezia secondary infections are common, and for cats it explains that antimicrobials can help when infection is confirmed by cytology and that topical treatment is preferred where possible. Whether to use them is judged by the veterinarian through tests.
Q What is allergen immunotherapy?
The Merck Veterinary Manual describes it as a method that aims to raise tolerance to allergens, and states that adverse events are rare, that the most common is increased itching, and that anaphylaxis is reported very rarely. For cats, it advises allowing 1 year before judging the effect.
Q Are these drugs prescription drugs in Korea?
The current Regulation on the Designation of Prescription Veterinary Drugs (처방대상 동물용의약품 지정에 관한 규정) on the National Law Information Center (Ministry of Agriculture, Food and Rural Affairs Public Notice No. 2020-90, in force from November 13, 2021) sets the active-ingredient drugs in Annex 5 and others as drugs that a wholesaler cannot sell without a prescription, and that list includes Prednisolone, Dexamethasone, Cyclosporine, Oclacitinib maleate and others. For veterinary pharmacy openers, Article 3 lists only injectable antibiotic preparations and injectable biological products. For specific products, check with the animal hospital and the current regulation.
Limits and scope of this guide
This article is an editorial draft, and no veterinary or pharmacy expert review has been completed. It does not replace diagnosis, drug selection or dosing for an individual pet, and doses were deliberately not covered. The evidence rests on the Merck Veterinary Manual, 1 US approved label and the Cornell Feline Health Center, and the original texts of the FDA Center for Veterinary Medicine and of WSAVA and ICADA could not be opened and checked. The Korean regulation's text and Annex 5 list in the current version (in force from November 13, 2021) were read as screen images; whether antihistamines, lokivetmab and ilunocitinib appear on the list could not be confirmed, nor could the approval status of products in Korea. The approval information for lokivetmab and ilunocitinib could also not be confirmed.
Translated from the Korean edition · Editorial draft, not professionally reviewed. The Korean edition is an explainer newly written from public sources; it is not a full translation of those sources. Veterinary expert review has not been completed. For decisions about your pet's health, talk to a veterinarian who knows your pet.
Sources and check dates
- Atopic Dermatitis in Dogs - Integumentary System ↗
Used as the basis for the drug groups in canine atopic dermatitis treatment (glucocorticoids, JAK inhibitors, lokivetmab, cyclosporine, antihistamines, essential fatty acids, immunotherapy, flea control, secondary infections) and the cautions for each group.
- Feline Atopic Skin Syndrome - Integumentary System ↗
Used as the basis for the explanations that oclacitinib is not approved in cats, steroid monitoring, cyclosporine adverse events, the limited benefit of antihistamines, and flea control being essential.
- APOQUEL (oclacitinib maleate) tablet, coated - label (라벨) ↗
Used as the basis for the wording on not using under 12 months, not using with serious infections, watching for infections and tumors, use with other immunosuppressants not evaluated, and not using in breeding, pregnant or nursing dogs.
- Flea Allergy (Cornell Feline Health Center) ↗
Used as the basis for the advice that the animal and the environment must be managed together in feline flea allergy, and for the wording not to use drugs without a veterinarian's specific recommendation.
- Regulation on the Designation of Prescription Veterinary Drugs (처방대상 동물용의약품 지정에 관한 규정) (Ministry of Agriculture, Food and Rural Affairs Public Notice No. 2020-90, in force November 13, 2021) ↗
Used as the basis for Articles 2 and 3 of the current version (the scope of drugs that cannot be sold without a prescription, by wholesaler and by veterinary pharmacy opener) and the Annex 5 active-ingredient list (Prednisolone, Dexamethasone, Cyclosporine, Oclacitinib maleate and others).
Korean edition checked · translated · each source may have a different check date. No paid partnerships.
This guide relies on 1 Korean law or notice. Current effective dates and upcoming amendments are listed on Korean law check status. This is not legal advice.
